XML 121 R98.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Jan. 02, 2022 | Jan. 03, 2021 | Dec. 29, 2019
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 93,775 | $ 82,584 | $ 82,059
Percentage Change In Sales By Segment Of Business | 13.60% | 0.60% |
Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 14,635 | $ 14,053 | 13,898
Percentage Change In Sales By Segment Of Business | 4.10% | 1.10% |
Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 52,080 | $ 45,572 | 42,198
Percentage Change In Sales By Segment Of Business | 14.30% | 8.00% |
Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 16,750 | $ 15,055 | 13,950
Percentage Change In Sales By Segment Of Business | 11.30% | 7.90% |
Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,861 | $ 3,574 | 3,413
Percentage Change In Sales By Segment Of Business | 64.00% | 4.70% |
Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 7,011 | $ 6,548 | 6,328
Percentage Change In Sales By Segment Of Business | 7.10% | 3.50% |
Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 14,548 | $ 12,367 | 10,692
Percentage Change In Sales By Segment Of Business | 17.60% | 15.70% |
Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,450 | $ 3,148 | 2,623
Percentage Change In Sales By Segment Of Business | 9.60% | 20.00% |
Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,460 | $ 4,878 | 5,192
Percentage Change In Sales By Segment Of Business | (8.60%) | (6.00%) |
Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 27,060 | $ 22,959 | 25,963
Percentage Change In Sales By Segment Of Business | 17.90% | (11.60%) |
Medical Devices | Interventional Solutions |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,971 | $ 3,046 | 2,997
Percentage Change In Sales By Segment Of Business | 30.40% | 1.60% |
Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 8,588 | $ 7,763 | 8,839
Percentage Change In Sales By Segment Of Business | 10.60% | (12.20%) |
Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 9,812 | $ 8,232 | 9,501
Percentage Change In Sales By Segment Of Business | 19.20% | (13.40%) |
Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,688 | $ 3,919 | 4,624
Percentage Change In Sales By Segment Of Business | 19.60% | (15.20%) |
OTC | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,227 | $ 4,824 | 4,444
Percentage Change In Sales By Segment Of Business | 8.40% | 8.50% |
Skin health/Beauty | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,541 | $ 4,450 | 4,593
Percentage Change In Sales By Segment Of Business | 2.00% | (3.10%) |
Oral Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,645 | $ 1,641 | 1,528
Percentage Change In Sales By Segment Of Business | 0.20% | 7.40% |
Baby Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,566 | $ 1,517 | 1,675
Percentage Change In Sales By Segment Of Business | 3.20% | (9.40%) |
Women's Health | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 917 | $ 901 | 986
Percentage Change In Sales By Segment Of Business | 1.80% | (8.60%) |
Wound Care and Other | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 739 | $ 720 | 671
Percentage Change In Sales By Segment Of Business | 2.60% | 7.20% |
Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,190 | $ 3,747 | 4,380
Percentage Change In Sales By Segment Of Business | (14.90%) | (14.40%) |
Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,276 | $ 2,243 | 2,188
Percentage Change In Sales By Segment Of Business | 1.40% | 2.60% |
Stelara | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 9,134 | $ 7,707 | 6,361
Percentage Change In Sales By Segment Of Business | 18.50% | 21.10% |
Tremfya | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,127 | $ 1,347 | 1,012
Percentage Change In Sales By Segment Of Business | 57.90% | 33.20% |
Other Immunology | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 24 | $ 11 | 10
Percentage Change In Sales By Segment Of Business |  | 6.40% |
COVID-19 | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 2,385 | $ 0 | 0
EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 994 | $ 964 | 861
Percentage Change In Sales By Segment Of Business | 3.10% | 11.90% |
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,083 | $ 2,184 | 2,110
Percentage Change In Sales By Segment Of Business | (4.60%) | 3.50% |
Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 399 | $ 427 | 441
Percentage Change In Sales By Segment Of Business | (6.50%) | (3.20%) |
CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 667 | $ 622 | 696
Percentage Change In Sales By Segment Of Business | 7.30% | (10.60%) |
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,022 | $ 3,653 | 3,330
Percentage Change In Sales By Segment Of Business | 10.10% | 9.70% |
RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 592 | $ 642 | 688
Percentage Change In Sales By Segment Of Business | (7.70%) | (6.80%) |
OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,729 | $ 1,632 | 1,614
Percentage Change In Sales By Segment Of Business | 6.00% | 1.10% |
DARZALEX | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,023 | $ 4,190 | 2,998
Percentage Change In Sales By Segment Of Business | 43.80% | 39.80% |
ERLEADA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,291 | $ 760 | 332
Percentage Change In Sales By Segment Of Business | 70.00% |  |
IMBRUVICA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,369 | $ 4,128 | 3,411
Percentage Change In Sales By Segment Of Business | 5.80% | 21.00% |
ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,297 | $ 2,470 | 2,795
Percentage Change In Sales By Segment Of Business | (7.00%) | (11.60%) |
Other Oncology | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 568 | $ 821 | 1,158
Percentage Change In Sales By Segment Of Business | (30.80%) | (29.10%) |
OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,819 | $ 1,639 | 1,327
Percentage Change In Sales By Segment Of Business | 11.00% | 23.50% |
UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,237 | $ 1,093 | 819
Percentage Change In Sales By Segment Of Business | 13.10% | 33.50% |
Other | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 395 | $ 416 | 476
Percentage Change In Sales By Segment Of Business | (5.00%) | (12.80%) |
Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 981 | $ 1,186 | 1,353
Percentage Change In Sales By Segment Of Business | (17.30%) | (12.40%) |
XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,438 | $ 2,345 | 2,313
Percentage Change In Sales By Segment Of Business | 4.00% | 1.40% |
INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 563 | $ 795 | 735
Percentage Change In Sales By Segment Of Business | (29.30%) | 8.20% |
PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 479 | $ 552 | 790
Percentage Change In Sales By Segment Of Business | (13.30%) | (30.20%) |
HIPS | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,485 | $ 1,280 | 1,438
Percentage Change In Sales By Segment Of Business | 16.00% | (11.00%) |
KNEES | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,325 | $ 1,170 | 1,480
Percentage Change In Sales By Segment Of Business | 13.30% | (21.00%) |
TRAUMA | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,885 | $ 2,614 | 2,720
Percentage Change In Sales By Segment Of Business | 10.40% | (3.90%) |
SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,893 | $ 2,699 | 3,201
Percentage Change In Sales By Segment Of Business | 7.20% | (15.70%) |
ADVANCED | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 4,622 | $ 3,839 | 4,095
Percentage Change In Sales By Segment Of Business | 20.40% | (6.20%) |
GENERAL | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,190 | $ 4,392 | 5,406
Percentage Change In Sales By Segment Of Business | 18.10% | (18.80%) |
CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,440 | $ 2,994 | 3,392
Percentage Change In Sales By Segment Of Business | 14.90% | (11.70%) |
SURGICAL | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,248 | $ 925 | 1,232
Percentage Change In Sales By Segment Of Business | 34.90% | (24.90%) |
United States |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 47,156 | $ 43,133 | 42,097
Percentage Change In Sales By Segment Of Business | 9.30% | 2.50% |
United States | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 6,516 | $ 6,362 | 5,839
Percentage Change In Sales By Segment Of Business | 2.40% | 9.00% |
United States | Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 27,954 | $ 25,735 | 23,874
Percentage Change In Sales By Segment Of Business | 8.60% | 7.80% |
United States | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 10,843 | $ 10,175 | 9,641
Percentage Change In Sales By Segment Of Business | 6.60% | 5.50% |
United States | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,249 | $ 1,735 | 1,597
Percentage Change In Sales By Segment Of Business | 29.70% | 8.60% |
United States | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,347 | $ 3,091 | 2,919
Percentage Change In Sales By Segment Of Business | 8.30% | 5.90% |
United States | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,958 | $ 5,092 | 4,299
Percentage Change In Sales By Segment Of Business | 17.00% | 18.50% |
United States | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,365 | $ 2,133 | 1,684
Percentage Change In Sales By Segment Of Business | 10.90% | 26.60% |
United States | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,192 | $ 3,509 | 3,734
Percentage Change In Sales By Segment Of Business | (9.00%) | (6.00%) |
United States | Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 12,686 | $ 11,036 | 12,384
Percentage Change In Sales By Segment Of Business | 14.90% | (10.90%) |
United States | Medical Devices | Interventional Solutions |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,836 | $ 1,452 | 1,443
Percentage Change In Sales By Segment Of Business | 26.40% | 0.60% |
United States | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,126 | $ 4,779 | 5,319
Percentage Change In Sales By Segment Of Business | 7.30% | (10.20%) |
United States | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,867 | $ 3,249 | 3,828
Percentage Change In Sales By Segment Of Business | 19.00% | (15.10%) |
United States | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,857 | $ 1,557 | 1,794
Percentage Change In Sales By Segment Of Business | 19.30% | (13.20%) |
United States | OTC | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,594 | $ 2,460 | 2,010
Percentage Change In Sales By Segment Of Business | 5.40% | 22.40% |
United States | Skin health/Beauty | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,400 | $ 2,350 | 2,392
Percentage Change In Sales By Segment Of Business | 2.10% | (1.70%) |
United States | Oral Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 637 | $ 683 | 621
Percentage Change In Sales By Segment Of Business | (6.70%) | 9.90% |
United States | Baby Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 378 | $ 376 | 362
Percentage Change In Sales By Segment Of Business | 0.50% | 3.70% |
United States | Women's Health | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 13 | $ 13 | 12
Percentage Change In Sales By Segment Of Business | (1.60%) | 8.20% |
United States | Wound Care and Other | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 495 | $ 480 | 441
Percentage Change In Sales By Segment Of Business | 3.10% | 8.90% |
United States | Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,019 | $ 2,508 | 3,079
Percentage Change In Sales By Segment Of Business | (19.50%) | (18.50%) |
United States | Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,127 | $ 1,155 | 1,159
Percentage Change In Sales By Segment Of Business | (2.40%) | (0.30%) |
United States | Stelara | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,938 | $ 5,240 | 4,346
Percentage Change In Sales By Segment Of Business | 13.30% | 20.60% |
United States | Tremfya | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,503 | $ 926 | 764
Percentage Change In Sales By Segment Of Business | 62.30% | 21.30% |
United States | Other Immunology | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 21 | $ 0 | 0
Percentage Change In Sales By Segment Of Business |  | 0.00% |
United States | COVID-19 | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | 634 | $ 0 | 0
United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 41 | $ 44 | 50
Percentage Change In Sales By Segment Of Business | (7.60%) | (11.20%) |
United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,508 | $ 1,587 | 1,422
Percentage Change In Sales By Segment Of Business | (4.90%) | 11.60% |
United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 66 | $ 104 | 126
Percentage Change In Sales By Segment Of Business | (36.00%) | (17.60%) |
United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 172 | $ 183 | 233
Percentage Change In Sales By Segment Of Business | (5.80%) | (21.40%) |
United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,550 | $ 2,314 | 2,107
Percentage Change In Sales By Segment Of Business | 10.20% | 9.80% |
United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 287 | $ 296 | 314
Percentage Change In Sales By Segment Of Business | (2.90%) | (5.90%) |
United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 338 | $ 298 | 266
Percentage Change In Sales By Segment Of Business | 13.30% | 12.40% |
United States | DARZALEX | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,169 | $ 2,232 | 1,567
Percentage Change In Sales By Segment Of Business | 42.00% | 42.40% |
United States | ERLEADA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 813 | $ 583 | 297
Percentage Change In Sales By Segment Of Business | 39.30% | 96.10% |
United States | IMBRUVICA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,747 | $ 1,821 | 1,555
Percentage Change In Sales By Segment Of Business | (4.00%) | 17.10% |
United States | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 119 | $ 373 | 810
Percentage Change In Sales By Segment Of Business | (68.10%) | (54.00%) |
United States | Other Oncology | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 110 | $ 83 | 70
Percentage Change In Sales By Segment Of Business | 31.70% | 18.60% |
United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,147 | $ 1,008 | 766
Percentage Change In Sales By Segment Of Business | 13.70% | 31.70% |
United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,056 | $ 955 | 714
Percentage Change In Sales By Segment Of Business | 10.50% | 33.80% |
United States | Other | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 163 | $ 169 | 205
Percentage Change In Sales By Segment Of Business | (3.70%) | (17.60%) |
United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 223 | $ 323 | 380
Percentage Change In Sales By Segment Of Business | (31.00%) | (15.10%) |
United States | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,438 | $ 2,345 | 2,313
Percentage Change In Sales By Segment Of Business | 4.00% | 1.40% |
United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 308 | $ 564 | 536
Percentage Change In Sales By Segment Of Business | (45.40%) | 5.20% |
United States | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 223 | $ 277 | 505
Percentage Change In Sales By Segment Of Business | (19.70%) | (45.10%) |
United States | HIPS | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 883 | $ 793 | 863
Percentage Change In Sales By Segment Of Business | 11.40% | (8.20%) |
United States | KNEES | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 787 | $ 743 | 889
Percentage Change In Sales By Segment Of Business | 5.90% | (16.40%) |
United States | TRAUMA | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,819 | $ 1,648 | 1,652
Percentage Change In Sales By Segment Of Business | 10.40% | (0.20%) |
United States | SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,637 | $ 1,595 | 1,915
Percentage Change In Sales By Segment Of Business | 2.60% | (16.70%) |
United States | ADVANCED | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,761 | $ 1,535 | 1,637
Percentage Change In Sales By Segment Of Business | 14.90% | (6.20%) |
United States | GENERAL | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,105 | $ 1,714 | 2,192
Percentage Change In Sales By Segment Of Business | 22.70% | (21.80%) |
United States | CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,398 | $ 1,213 | 1,304
Percentage Change In Sales By Segment Of Business | 15.20% | (7.00%) |
United States | SURGICAL | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 459 | $ 344 | 490
Percentage Change In Sales By Segment Of Business | 33.50% | (29.70%) |
Non-US |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 46,619 | $ 39,451 | 39,962
Percentage Change In Sales By Segment Of Business | 18.20% | (1.30%) |
Non-US | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 8,119 | $ 7,691 | 8,059
Percentage Change In Sales By Segment Of Business | 5.60% | (4.60%) |
Non-US | Pharmaceutical |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 24,126 | $ 19,837 | 18,324
Percentage Change In Sales By Segment Of Business | 21.60% | 8.30% |
Non-US | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,907 | $ 4,880 | 4,309
Percentage Change In Sales By Segment Of Business | 21.00% | 13.20% |
Non-US | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,612 | $ 1,839 | 1,815
Percentage Change In Sales By Segment Of Business | 96.30% | 1.30% |
Non-US | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,664 | $ 3,457 | 3,409
Percentage Change In Sales By Segment Of Business | 6.00% | 1.40% |
Non-US | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 8,590 | $ 7,275 | 6,393
Percentage Change In Sales By Segment Of Business | 18.10% | 13.80% |
Non-US | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,085 | $ 1,015 | 939
Percentage Change In Sales By Segment Of Business | 6.90% | 8.20% |
Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,268 | $ 1,369 | 1,458
Percentage Change In Sales By Segment Of Business | (7.40%) | (6.10%) |
Non-US | Medical Devices |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 14,374 | $ 11,923 | 13,579
Percentage Change In Sales By Segment Of Business | 20.60% | (12.20%) |
Non-US | Medical Devices | Interventional Solutions |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,135 | $ 1,594 | 1,554
Percentage Change In Sales By Segment Of Business | 34.00% | 2.60% |
Non-US | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,462 | $ 2,984 | 3,520
Percentage Change In Sales By Segment Of Business | 16.00% | (15.20%) |
Non-US | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 5,945 | $ 4,983 | 5,673
Percentage Change In Sales By Segment Of Business | 19.30% | (12.20%) |
Non-US | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,831 | $ 2,362 | 2,830
Percentage Change In Sales By Segment Of Business | 19.80% | (16.50%) |
Non-US | OTC | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,634 | $ 2,364 | 2,434
Percentage Change In Sales By Segment Of Business | 11.40% | (2.90%) |
Non-US | Skin health/Beauty | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,141 | $ 2,100 | 2,201
Percentage Change In Sales By Segment Of Business | 1.90% | (4.60%) |
Non-US | Oral Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,008 | $ 958 | 906
Percentage Change In Sales By Segment Of Business | 5.10% | 5.70% |
Non-US | Baby Care | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,188 | $ 1,141 | 1,313
Percentage Change In Sales By Segment Of Business | 4.10% | (13.10%) |
Non-US | Women's Health | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 905 | $ 888 | 974
Percentage Change In Sales By Segment Of Business | 1.80% | (8.80%) |
Non-US | Wound Care and Other | Consumer Health |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 243 | $ 240 | 230
Percentage Change In Sales By Segment Of Business | 1.70% | 4.10% |
Non-US | Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 935 | $ 893 | 1,007
Percentage Change In Sales By Segment Of Business | 4.80% | (11.40%) |
Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,148 | $ 1,088 | 1,029
Percentage Change In Sales By Segment Of Business | 5.50% | 5.80% |
Non-US | Stelara | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,196 | $ 2,467 | 2,015
Percentage Change In Sales By Segment Of Business | 29.60% | 22.40% |
Non-US | Tremfya | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 624 | $ 421 | 248
Percentage Change In Sales By Segment Of Business | 48.20% | 69.90% |
Non-US | Other Immunology | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3 | $ 11 | 10
Percentage Change In Sales By Segment Of Business | (73.30%) | 6.40% |
Non-US | COVID-19 | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,751 | $ 0 | 0
Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 953 | $ 920 | 812
Percentage Change In Sales By Segment Of Business | 3.60% | 13.30% |
Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 575 | $ 597 | 689
Percentage Change In Sales By Segment Of Business | (3.60%) | (13.40%) |
Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 333 | $ 323 | 315
Percentage Change In Sales By Segment Of Business | 3.00% | 2.60% |
Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 495 | $ 439 | 463
Percentage Change In Sales By Segment Of Business | 12.80% | (5.10%) |
Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,472 | $ 1,339 | 1,224
Percentage Change In Sales By Segment Of Business | 10.00% | 9.40% |
Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 305 | $ 346 | 374
Percentage Change In Sales By Segment Of Business | (11.80%) | (7.50%) |
Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,391 | $ 1,334 | 1,349
Percentage Change In Sales By Segment Of Business | 4.30% | (1.10%) |
Non-US | DARZALEX | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,854 | $ 1,958 | 1,430
Percentage Change In Sales By Segment Of Business | 45.80% | 36.90% |
Non-US | ERLEADA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 478 | $ 176 | 35
Non-US | IMBRUVICA | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,622 | $ 2,307 | 1,856
Percentage Change In Sales By Segment Of Business | 13.60% | 24.30% |
Non-US | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,178 | $ 2,097 | 1,985
Percentage Change In Sales By Segment Of Business | 3.90% | 5.60% |
Non-US | Other Oncology | Pharmaceutical | Oncology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 458 | $ 738 | 1,087
Percentage Change In Sales By Segment Of Business | (37.90%) | (32.10%) |
Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 672 | $ 631 | 562
Percentage Change In Sales By Segment Of Business | 6.60% | 12.30% |
Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 181 | $ 138 | 105
Percentage Change In Sales By Segment Of Business | 31.10% | 30.90% |
Non-US | Other | Pharmaceutical | Pulmonary Hypertension |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 232 | $ 247 | 272
Percentage Change In Sales By Segment Of Business | (5.90%) | (9.20%) |
Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 758 | $ 864 | 974
Percentage Change In Sales By Segment Of Business | (12.20%) | (11.30%) |
Non-US | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 0 | $ 0 | 0
Percentage Change In Sales By Segment Of Business | 0.00% | 0.00% |
Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 254 | $ 231 | 199
Percentage Change In Sales By Segment Of Business | 9.90% | 16.30% |
Non-US | PROCRIT/EPREX | Pharmaceutical | Cardiovascular/Metabolism/Other |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 256 | $ 274 | 285
Percentage Change In Sales By Segment Of Business | (6.80%) | (3.80%) |
Non-US | HIPS | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 602 | $ 487 | 575
Percentage Change In Sales By Segment Of Business | 23.60% | (15.30%) |
Non-US | KNEES | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 538 | $ 427 | 591
Percentage Change In Sales By Segment Of Business | 26.10% | (27.80%) |
Non-US | TRAUMA | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,066 | $ 966 | 1,068
Percentage Change In Sales By Segment Of Business | 10.40% | (9.60%) |
Non-US | SPINE,SPORTS & OTHER | Medical Devices | Orthopaedics |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 1,256 | $ 1,104 | 1,286
Percentage Change In Sales By Segment Of Business | 13.80% | (14.10%) |
Non-US | ADVANCED | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,861 | $ 2,304 | 2,458
Percentage Change In Sales By Segment Of Business | 24.10% | (6.20%) |
Non-US | GENERAL | Medical Devices | Surgery |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 3,085 | $ 2,679 | 3,215
Percentage Change In Sales By Segment Of Business | 15.20% | (16.70%) |
Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 2,043 | $ 1,781 | 2,088
Percentage Change In Sales By Segment Of Business | 14.70% | (14.70%) |
Non-US | SURGICAL | Medical Devices | Vision |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 788 | $ 581 | 742
Percentage Change In Sales By Segment Of Business | 35.70% | (21.70%) |
UNITED STATES Exports | Remicade | Pharmaceutical | Immunology |  |  |
Segment Reporting Information [Line Items] |  |  |
Sales to Customers | $ 236 | $ 346 | $ 294
Percentage Change In Sales By Segment Of Business | (31.90%) | 18.00% |

X
- Definition Percentage change in sales by segment of business. + References No definition available. + Details
Name: | jnj_PercentageChangeInSalesBySegmentOfBusiness
Namespace Prefix: | jnj_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_ImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=jnj_VisionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_BabyCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_StelaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TremfyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherImmunologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_COVID19Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_DARZALEXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ErleadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_IMBRUVICAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ZYTIGAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherOncologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OPSUMITMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_UPTRAVIMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_OtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_XareltoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_PROCRITEPREXMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_HIPSMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_KNEESMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_TRAUMAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_ADVANCEDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_GENERALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=jnj_SURGICALMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |